Catherine Longeval participates in a Dual Dialogue on "Legal Considerations Regarding the Use of Unapproved Products" at the EU Pharmaceutical Law Forum’s virtual conference 2020
- 19/11/2020
- News
On 18 November 2020, Van Bael & Bellis partner Catherine Longeval participated as a speaker in a Dual Dialogue on "Legal Considerations Regarding the Use of Unapproved Products" at the EU Pharmaceutical Law Forum’s virtual conference 2020. Catherine’s co-speaker was Hilary Jones, Senior Director, Cell Therapy & Regulatory Law of Gilead Sciences Europe Ltd, and the session was chaired by Jordi Faus of Faus & Moliner. The Dual Dialogue covered the hospital exemption, the rise in the use of the compassionate use mechanism, recent developments regarding unapproved and off-label products, compounding and the legal challenges and wider implications for the industry.
